179 related articles for article (PubMed ID: 11741162)
1. Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen.
Casado JL; Moreno S; Hertogs K; Dronda F; Antela A; Dehertogh P; Perez-Elías MJ; Moreno A;
AIDS; 2002 Jan; 16(1):47-52. PubMed ID: 11741162
[TBL] [Abstract][Full Text] [Related]
2. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
[TBL] [Abstract][Full Text] [Related]
5. Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.
Middleton T; Smith D; Larder B; Law M; Birch C
HIV Clin Trials; 2001; 2(6):445-52. PubMed ID: 11742431
[TBL] [Abstract][Full Text] [Related]
6. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).
Pellegrin I; Breilh D; Montestruc F; Caumont A; Garrigue I; Morlat P; Le Camus C; Saux MC; Fleury HJ; Pellegrin JL
AIDS; 2002 Jul; 16(10):1331-40. PubMed ID: 12131209
[TBL] [Abstract][Full Text] [Related]
7. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
Schapiro JM; Winters MA; Lawrence J; Merigan TC
AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
[TBL] [Abstract][Full Text] [Related]
8. Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir.
Tebas P; Patick AK; Kane EM; Klebert MK; Simpson JH; Erice A; Powderly WG; Henry K
AIDS; 1999 Feb; 13(2):F23-8. PubMed ID: 10202820
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens.
Hall CS; Raines CP; Barnett SH; Moore RD; Gallant JE
AIDS; 1999 Jul; 13(10):1207-12. PubMed ID: 10416524
[TBL] [Abstract][Full Text] [Related]
10. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
[TBL] [Abstract][Full Text] [Related]
11. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.
Lorenzi P; Opravil M; Hirschel B; Chave JP; Furrer HJ; Sax H; Perneger TV; Perrin L; Kaiser L; Yerly S
AIDS; 1999 Feb; 13(2):F17-21. PubMed ID: 10202819
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of nelfinavir in patients switched from ritonavir/saquinavir combination antiretroviral therapy.
Hellinger JA; Cohen CJ; Stein AJ; Gallant JE; Gathe J; Keiser P
HIV Clin Trials; 2000; 1(2):25-8. PubMed ID: 11590495
[TBL] [Abstract][Full Text] [Related]
13. [HIV genotypic mutation selectively induced by the protease inhibitor nelfinavir at codon 30. Case series and consequences for antiretroviral management].
Manfredi R; Calza L
Infez Med; 2002 Sep; 10(3):151-6. PubMed ID: 12704265
[TBL] [Abstract][Full Text] [Related]
14. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Marcelin AG; Dalban C; Peytavin G; Lamotte C; Agher R; Delaugerre C; Wirden M; Conan F; Dantin S; Katlama C; Costagliola D; Calvez V
Antimicrob Agents Chemother; 2004 Dec; 48(12):4687-92. PubMed ID: 15561845
[TBL] [Abstract][Full Text] [Related]
15. Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly protease inhibitor-experienced HIV-infected patients.
Chavanet P; Piroth L; Grappin M; Buisson M; Gourdon F; Cabié A; Duong M; Brunel-Dalmas F; Peytavin G; Portier H
HIV Clin Trials; 2001; 2(5):408-12. PubMed ID: 11673815
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
Valer L; de Mendoza C; Soriano V
J Med Virol; 2005 Dec; 77(4):460-4. PubMed ID: 16254964
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of a nelfinavir- and nevirapine-containing salvage regimen.
Sullivan AK; Nelson MR; Shaw A; Moyle GJ; Mandalia S; Gazzard BG; Asboe D
HIV Clin Trials; 2000; 1(1):7-12. PubMed ID: 11590484
[TBL] [Abstract][Full Text] [Related]
18. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).
Vray M; Meynard JL; Dalban C; Morand-Joubert L; Clavel F; Brun-Vézinet F; Peytavin G; Costagliola D; Girard PM;
Antivir Ther; 2003 Oct; 8(5):427-34. PubMed ID: 14640390
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.
Yilmaz A; Fuchs D; Hagberg L; Nillroth U; Ståhle L; Svensson JO; Gisslén M
BMC Infect Dis; 2006 Mar; 6():63. PubMed ID: 16566834
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.
Dronda F; Casado JL; Moreno S; Hertogs K; García-Arata I; Antela A; Pérez-Elías MJ; Ruiz L; Larder B;
AIDS Res Hum Retroviruses; 2001 Feb; 17(3):211-5. PubMed ID: 11177403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
